000164361 001__ 164361
000164361 005__ 20180913060528.0
000164361 0247_ $$2doi$$a10.1186/1472-6807-9-7
000164361 022__ $$a1472-6807
000164361 037__ $$aARTICLE
000164361 245__ $$aThe structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)
000164361 269__ $$a2009
000164361 260__ $$bBioMed Central$$c2009
000164361 336__ $$aJournal Articles
000164361 520__ $$aImatinib represents the first in a class of drugs targeted against chronic myelogenous leukemia to enter the clinic, showing excellent efficacy and specificity for Abl, Kit, and PDGFR kinases. Recent screens carried out to find off-target proteins that bind to imatinib identified the oxidoreductase NQO2, a flavoprotein that is phosphorylated in a chronic myelogenous leukemia cell line.
000164361 700__ $$aWinger, Jonathan A.
000164361 700__ $$0245280$$aHantschel, Oliver$$g209845
000164361 700__ $$aSuperti-Furga, Giulio
000164361 700__ $$aKuriyan, John
000164361 773__ $$j9$$q7$$tBMC structural biology
000164361 8564_ $$s4648489$$uhttps://infoscience.epfl.ch/record/164361/files/1472-6807-9-7.pdf$$yPublisher's version$$zn/a
000164361 909C0 $$0252328$$pUPHAN$$xU12375
000164361 909CO $$ooai:infoscience.tind.io:164361$$pSV$$particle
000164361 917Z8 $$x182396
000164361 937__ $$aEPFL-ARTICLE-164361
000164361 973__ $$aOTHER$$rREVIEWED$$sPUBLISHED
000164361 980__ $$aARTICLE